Table 2. Mutational profiling of MSS tumors and MSI-H tumors.
| Gene* | MSS (n = 113) | MSI-H (n = 29) | P value |
|---|---|---|---|
| APC | 53 (47%) | 10 (34%) | 0.23 |
| BRAF | 6 (5%)† | 10 (34%) | <0.001 |
| CTNNB1 | 6 (5%) | 1 (3%) | 1 |
| FBXW7 | 6 (5%) | 4 (14%) | 0.12 |
| KRAS | 52 (46%) | 9 (31%) | 0.15 |
| NRAS | 5 (4%) | 3 (10%) | 0.36 |
| PIK3CA | 17 (15%) | 10 (34%) | 0.02 |
| SMAD4 | 12 (11%) | 0 (0%) | 0.13 |
| TP53 | 71 (63%) | 9 (31%) | <0.01 |
| AKT1 | 1 (1%) | 1 (3%) | 0.30 |
| PTEN | 3 (3%) | 8 (28%) | <0.001 |
| mTOR‡ | 20 (18%) | 17 (59%) | <0.001 |
*
The 9 most commonly mutated genes in CRC are listed at the top.
†
4 p.V600E and 2 p.D594G mutations.
‡
mTOR pathway: mutation in PIK3CA, PTEN and/or AKT1 genes.